Does TECLISTAMAB-CQYV Cause Progressive multifocal leukoencephalopathy? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Progressive multifocal leukoencephalopathy have been filed in association with TECLISTAMAB-CQYV. This represents 0.9% of all adverse event reports for TECLISTAMAB-CQYV.
14
Reports of Progressive multifocal leukoencephalopathy with TECLISTAMAB-CQYV
0.9%
of all TECLISTAMAB-CQYV reports
3
Deaths
9
Hospitalizations
How Dangerous Is Progressive multifocal leukoencephalopathy From TECLISTAMAB-CQYV?
Of the 14 reports, 3 (21.4%) resulted in death, 9 (64.3%) required hospitalization, and 4 (28.6%) were considered life-threatening.
Is Progressive multifocal leukoencephalopathy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TECLISTAMAB-CQYV. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does TECLISTAMAB-CQYV Cause?
Cytokine release syndrome (406)
Immune effector cell-associated neurotoxicity syndrome (153)
Off label use (122)
Death (116)
Plasma cell myeloma (96)
Infection (83)
Neutropenia (74)
Fatigue (72)
Pyrexia (67)
Covid-19 (64)
What Other Drugs Cause Progressive multifocal leukoencephalopathy?
NATALIZUMAB (1,668)
RITUXIMAB (1,647)
CYCLOPHOSPHAMIDE (782)
PREDNISONE (606)
PREDNISOLONE (439)
TACROLIMUS (438)
METHOTREXATE (428)
DOXORUBICIN (421)
MYCOPHENOLATE MOFETIL (414)
VINCRISTINE (376)
Which TECLISTAMAB-CQYV Alternatives Have Lower Progressive multifocal leukoencephalopathy Risk?
TECLISTAMAB-CQYV vs TEDIZOLID
TECLISTAMAB-CQYV vs TEDUGLUTIDE
TECLISTAMAB-CQYV vs TEDUGLUTIDE\WATER
TECLISTAMAB-CQYV vs TEGAFUR
TECLISTAMAB-CQYV vs TEGAFUR\URACIL